Delving into the Latest Updates on Pfizer Pharmaceuticals Korea Ltd. with Synapse

概览

疾病领域	数量

神经系统疾病	3
内分泌与代谢疾病	3
肿瘤	3
感染	2
血液及淋巴系统疾病	2
免疫系统疾病	1

排名前五的药物类型	数量

小分子化药	5
ADC	1
激素	1
预防性疫苗	1
mRNA疫苗	1

排名前五的靶点	数量

TTR(转甲状腺素蛋白)	2
SARS-CoV-2 S protein(新冠病毒刺突蛋白)	1
GHR(生长激素受体)	1
fungal CYP51A1(真菌细胞色素P450家族成员51)	1
EGFR x EGFR L858R x EGFR-Ex19del x HER2 x HER4	1

关联

8

项与 Pfizer Pharmaceuticals Korea Ltd. 相关的药物

Somatrogon(OPKO Health, Inc.)

靶点

GHR

作用机制

GHR激动剂

在研机构

OPKO Health, Inc. [+7]

原研机构

OPKO Health, Inc.

在研适应症

侏儒症 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2021-10-26

Comirnaty-COVID-19 mRNA vaccine

复必泰

靶点

SARS-CoV-2 S protein

作用机制

SARS-CoV-2 S protein调节剂 [+1]

在研机构

BioNTech Manufacturing GmbH [+7]

原研机构

BioNTech SE

在研适应症

新型冠状病毒感染

非在研适应症

流感病毒感染 [+1]

最高研发阶段批准上市

首次获批国家/地区

英国

首次获批日期2020-12-02

Tafamidis

氯苯唑酸

靶点

TTR

作用机制

TTR调节剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2019-05-03

100 项与 Pfizer Pharmaceuticals Korea Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Pfizer Pharmaceuticals Korea Ltd. 相关的专利（医药）

登录后查看更多信息

65

项与 Pfizer Pharmaceuticals Korea Ltd. 相关的文献（医药）

2024-02-01·Journal of Hospital Infection

Disease burden of bacteraemia with extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales in Korea

Article

作者: Kim, B ; Moon, S M ; Ahn, J ; Park, K-H ; Kwak, Y G ; Gil, H-Y ; Song, K-H ; Kim, H B ; Park, W B ; Kim, C-J ; Lee, C M ; Kim, Y S ; Lee, S ; Kim, Y K ; Kim, E S

BACKGROUNDDespite the significant impact of multi-drug-resistant bacteraemia, especially extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) and carbapenem-resistant Enterobacterales (CRE), the burden of disease has not been investigated thoroughly.AIMTo evaluate the clinical outcomes and socio-economic burden of ESBL-E and CRE bacteraemia nationwide in the Republic of Korea.METHODSA search was undertaken for all cases of ESBL-E and CRE bacteraemia and matched controls in 10 hospitals in the Republic of Korea over 6 months. Patients with ESBL-E or CRE bacteraemia were classified as the R group, and matched controls with antibiotic-susceptible bacteraemia and without infection were classified as the S and N groups, respectively. Patients' clinical data were collected, and the economic burden was estimated based on medical expenses, loss of productivity and total costs.FINDINGSIn total, 795 patients were identified, including 265 patients with ESBL-E or CRE bacteraemia and their matched controls. The mean total length of stay for patients with ESBL-E and CRE in the R group was 1.53 and 1.90 times that of patients in the S group, respectively. The 90-day mortality rates for ESBL-E in the R and S groups were 12.1% and 5.6%, respectively, and the corresponding figures for CRE were 28.6% and 12.0%. There were significant differences in the total costs between the R, S and N groups for both ESBL-E and CRE (ESBL-E: $11,151 vs $8712 vs $6063, P=0.004; CRE: $40,464 vs $8748 vs $7279, P=0.024).CONCLUSIONThe clinical and economic burden imposed by ESBL-E or CRE bacteraemia was extremely high. These findings suggest that efforts to control resistant bacteraemia are necessary to reduce this burden.

2023-10-01·Annals of dermatology

Hospital Utilization and Medication Prescriptions among Patients with Atopic Dermatitis in South Korea: A Real-World Data Analysis.

Article

作者: Shin, Ju-Young ; Jeon, Ja-Young ; Oh, In-Sun ; Choi, Ahhyung ; Lee, Ji Hyun ; Son, Sang Wook ; Noh, Yunha ; Yoo, Hyun-Jeong

2023-06-01·BMJ Open

Longitudinal trajectories of sedation level and clinical outcomes in patients who are mechanically ventilated based on a group-based trajectory model: a prospective, multicentre, longitudinal and observational study in Korea

Article

作者: Lim, Chae-Man ; Yun, Choa ; Ahn, Jee Hwan ; Hyun, Dong-Gon ; Nam, Chung Mo ; Gil, Ha-Yeong

ObjectivesChanges in sedation levels over a long time in patients who are mechanically ventilated are unknown. Therefore, we investigated the long-term sedation levels of these patients by classifying them into different longitudinal patterns.DesignThis was a multicentre, prospective, longitudinal, and observational study.SettingTwenty intensive care units (ICUs) spanning several medical institutions in Korea.ParticipantsPatients who received mechanical ventilation and sedatives in ICU within 48 hours of admission between April 2020 and July 2021.Primary and secondary outcome measuresThe primary objective of this study was to identify the pattern of sedation practice. Additionally, we analysed the associations of trajectory groups with clinical outcomes as the secondary outcome.ResultsSedation depth was monitored using Richmond Agitation-Sedation Scale (RASS). A group-based trajectory model was used to classify 631 patients into four trajectories based on sedation depth: persistent suboptimal (13.2%, RASS ≤ −3 throughout the first 30 days), delayed lightening (13.9%, RASS ≥ −2 after the first 15 days), early lightening (38.4%, RASS ≥ −2 after the first 7 days) and persistent optimal (34.6%, RASS ≥ −2 during the first 30 days). ‘Persistent suboptimal’ trajectory was associated with delayed extubation (HR: 0.23, 95% CI: 0.16 to 0.32, p<0.001), longer ICU stay (HR: 0.36, 95% CI: 0.26 to 0.51, p<0.001) and hospital mortality (HR: 13.62, 95% CI: 5.99 to 30.95, p<0.001) compared with ‘persistent optimal’. The ‘delayed lightening’ and ‘early lightening’ trajectories showed lower extubation probability (HR: 0.30, 95% CI: 0.23 to 0.41, p<0.001; HR: 0.72, 95% CI: 0.59 to 0.87, p<0.001, respectively) and ICU discharge (HR: 0.44, 95% CI: 0.33 to 0.59, p<0.001 and HR: 0.80, 95% CI: 0.65 to 0.97, p=0.024) compared with ‘persistently optimal’.ConclusionsAmong the four trajectories, ‘persistent suboptimal’ trajectory was associated with higher mortality.

100 项与 Pfizer Pharmaceuticals Korea Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Pfizer Pharmaceuticals Korea Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

8

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

氯苯唑酸 ( TTR )	甲状腺素运载蛋白淀粉样变心肌病更多	批准上市
硫酸艾沙康唑鎓 ( fungal CYP51A1 )	侵袭性曲霉菌病更多	批准上市
氯苯唑酸葡甲胺 ( TTR )	甲状腺素运载蛋白淀粉样变心肌病更多	批准上市
复必泰 ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	批准上市
伯舒替尼 ( Bcr-Abl x SRC )	费城染色体阳性慢性粒细胞白血病更多	批准上市